Iran (Islamic Republic of)Tuberculosis profile
Population  2016 80 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.85 (0.83–0.88) 1.1 (1–1.1)
Mortality (HIV+TB only) 0.037 (0.012–0.076) 0.05 (0.02–0.09)
Incidence  (includes HIV+TB) 12 (8.9–15) 14 (11–18)
Incidence (HIV+TB only) 0.35 (0.23–0.5) 0.44 (0.28–0.62)
Incidence (MDR/RR-TB)** 0.2 (0.12–0.29) 0.25 (0.14–0.36)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.62 (0.46–0.77) 4.8 (3.6–6) 5.4 (4.1–6.8)
Males 0.7 (0.53–0.88) 5.4 (4.1–6.8) 6.1 (4.6–7.7)
Total 1.3 (0.99–1.7) 10 (7.7–13) 12 (8.9–15)
TB case notifications, 2016  
Total cases notified 9 454
Total new and relapse 9 252
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 65%
          - % pulmonary 72%
          - % bacteriologically confirmed among pulmonary 74%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 80% (63–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.08 (0.06–0.1)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 351 6%
          - on antiretroviral therapy 151 43%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  130
(82–170)
Estimated % of TB cases with MDR/RR-TB 1.3% (0.6–2) 8.3% (5.9–11)  
% notified tested for rifampicin resistance 11% 65% 1 585
MDR/RR-TB cases tested for resistance to second-line drugs   17
Laboratory-confirmed cases MDR/RR-TB: 53, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 49, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 87% 10 173
Previously treated cases, excluding relapse, registered in 2015 78% 201
HIV-positive TB cases registered in 2015 66% 299
MDR/RR-TB cases started on second-line treatment in 2014 58% 48
XDR-TB cases started on second-line treatment in 2014 0% 2
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment 10%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (100–100)
TB financing, 2017  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-12-12 Data: www.who.int/tb/data